All In Biotech

Drug Trial Radar · NCT06125951

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial With an Open-Label Extension Phase to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

247

Actual

Start

Apr 12, 2024

Primary completion

Sep 22, 2026

Study completion Feb 2028

Sponsor

Lead sponsor
Actinogen MedicalIndustry
Sponsor type
Industry
First posted
Nov 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.

Conditions

  • Dementia Moderate
  • Dementia, Mild
  • Alzheimer Disease

Interventions

  • XanamemDrug

    Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

  • PlaceboDrug

    Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of 10 mg Xanamem on integrated cognitive and functional abilitiesTime frame: 36 weeks
  2. Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]Time frame: 36 weeks

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • ACW Investigative Site 218

    Carlsbad, California

  • ACW Investigative Site 209

    Sherman Oaks, California

  • ACW Investigative Site 211

    Denver, Colorado

  • ACW Investigative Site 208

    Englewood, Colorado

  • ACW Investigative Site 203

    Delray Beach, Florida

  • ACW Investigative site 201

    Miami, Florida

  • ACW Investigative site 202

    New Port Richey, Florida

  • ACW Investigative site 204

    Orlando, Florida

  • ACW Investigative site 205

    The Villages, Florida

  • ACW Investigative Site 207

    Decatur, Georgia

  • ACW Investigative Site 206

    Marlton, New Jersey

  • ACW Investigative Site 214

    Albany, New York

  • ACW Investigative Site 219

    Staten Island, New York

  • ACW Investigative Site 210

    Dayton, Ohio

  • ACW Investigative Site 217

    Independence, Ohio

  • ACW Investigative Site 212

    Portland, Oregon

  • ACW Investigative Site 216

    East Providence, Rhode Island

  • ACW Investigative Site 220

    Austin, Texas

  • ACW Investigative Site 215

    Bellevue, Washington

  • ACW Investigative Site 106

    Darlinghurst, New South Wales, Australia

  • ACW Investigative Site 103

    Erina, New South Wales, Australia

  • ACW Investigative Site 102

    Kogarah, New South Wales, Australia

  • ACW Investigative Site 107

    Macquarie Park, New South Wales, Australia

  • ACW Investigative Site 111

    Newcastle, New South Wales, Australia

  • ACW Investigative Site 113

    Birtinya, Queensland, Australia

  • ACW Investigative Site 105

    Chermside, Queensland, Australia

  • ACW Investigative Site 114

    Bedford Park, South Australia, Australia

  • ACW Investigative Site 110

    Woodville South, South Australia, Australia

  • ACW Investigative Site 115

    Carlton, Victoria, Australia

  • ACW Investigative Site 101

    Ivanhoe, Victoria, Australia

  • ACW Investigative Site 108

    Malvern, Victoria, Australia

  • ACW Investigative Site 112

    Parkville, Victoria, Australia

  • ACW Investigative Site 104

    Nedlands, Western Australia, Australia

  • ACW Investigative Site 109

    West Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.